NAPE-PLD Antibody (E-8): sc-514372

NAPE-PLD Antibody (E-8) is a mouse monoclonal IgG1 kappa light chain antibody that detects NAPE-PLD of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). NAPE-PLD (E-8) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. NAPE-PLD, or N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D, is a crucial 393 amino acid membrane protein that functions as a phospholipase D type enzyme, hydrolyzing N-acyl-phosphatidylethanolamines (NAPEs) to generate N-acylethanolamines (NAEs) and phosphatidic acid. This enzymatic activity is vital for anandamide synthesis, a key endocannabinoid that interacts with cannabinoid receptors, influencing various physiological processes such as pain sensation, mood regulation, and appetite control. NAPE-PLD exists primarily as a monomer and binds one or two zinc ions per subunit, with activity being stimulated by divalent cations, highlighting the importance of metal ion interactions in function. NAPE-PLD is encoded on human chromosome 7, a region associated with several genetic disorders, underscoring potential implications in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

NAPE-PLD Antibody (E-8) References:

1. Molecular characterization of a phospholipase D generating anandamide and its congeners.  |  Okamoto, Y., et al. 2004. J Biol Chem. 279: 5298-305. PMID: 14634025
2. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids.  |  Leung, D., et al. 2006. Biochemistry. 45: 4720-6. PMID: 16605240
3. Lissencephaly 1 linking to multiple diseases: mental retardation, neurodegeneration, schizophrenia, male sterility, and more.  |  Reiner, O., et al. 2006. Neuromolecular Med. 8: 547-65. PMID: 17028375
4. [Williams-Beuren syndrome].  |  Gilbert-Dussardier, B. 2006. Rev Prat. 56: 2102-6. PMID: 17416045
5. Therapy-related leukemia and myelodysplasia: susceptibility and incidence.  |  Leone, G., et al. 2007. Haematologica. 92: 1389-98. PMID: 17768113
6. Localization of N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) expression in mouse brain: A new perspective on N-acylethanolamines as neural signaling molecules.  |  Egertová, M., et al. 2008. J Comp Neurol. 506: 604-15. PMID: 18067139
7. N-acylphosphatidylethanolamine, a gut- derived circulating factor induced by fat ingestion, inhibits food intake.  |  Gillum, MP., et al. 2008. Cell. 135: 813-24. PMID: 19041747
8. Fluorescence-Based NAPE-PLD Activity Assay.  |  Mock, ED., et al. 2023. Methods Mol Biol. 2576: 233-240. PMID: 36152191
9. NAPE-PLD deletion in stress-TRAPed neurons results in an anxiogenic phenotype.  |  Tevosian, M., et al. 2023. Transl Psychiatry. 13: 152. PMID: 37149657
10. Small Molecule Activation of NAPE-PLD Enhances Efferocytosis by Macrophages.  |  Zarrow, JE., et al. 2023. ACS Chem Biol. 18: 1891-1904. PMID: 37531659
11. NAPE-PLD regulates specific baseline affective behaviors but is dispensable for inflammatory hyperalgesia.  |  Chen, I., et al. 2023. Neurobiol Pain. 14: 100135. PMID: 38099275
12. Restriction fragment length polymorphism associated with the pro alpha 2(I) gene of human type I procollagen. Application to a family with an autosomal dominant form of osteogenesis imperfecta.  |  Tsipouras, P., et al. 1983. J Clin Invest. 72: 1262-7. PMID: 6313757

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-NAPE-PLD Antibody (E-8) has 4 citations in a variety of scientific publications.

Primary antibodies like Anti-NAPE-PLD Antibody (E-8) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

NAPE-PLD Antibody (E-8) Specifications

Alternate Product Name: NAPE-PLD

Product Clone Name: E-8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 115-193

Epitope Target: NAPE-PLD

Epitope Species: human

Product Reactivity/Detection: NAPE-PLD

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 4 citations in various scientific publications

Available Conjugates/Forms for NAPE-PLD Antibody (E-8): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin